Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.5 (
RNase P
)
1,348
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
External guide sequences (EGSs) represent a new class of RNA-based gene-targeting agents, consist of a sequence complementary to a target mRNA, and render the target RNA susceptible to degradation by
ribonuclease P
(
RNase P
). In this study, EGSs were constructed to target the mRNA encoding human CC-chemokine receptor 5 (
CCR5
), one of the primary coreceptors for HIV. An EGS RNA, C1, efficiently directed human
RNase P
to cleave the
CCR5
mRNA sequence in vitro. A reduction of about 70% in the expression level of both
CCR5
mRNA and protein and an inhibition of more than 50-fold in HIV (R5 strain Ba-L) p24 production were observed in cells that expressed C1. In comparison, a reduction of about 10% in the expression of
CCR5
and viral growth was found in cells that either did not express the EGS or produced a "disabled" EGS which carried nucleotide mutations that precluded
RNase P
recognition. Furthermore, the same C1-expressing cells that were protected from R5 strain Ba-L retained susceptibility to X4 strain IIIB, which uses CXCR4 as the coreceptor instead of
CCR5
, suggesting that the
RNase P
-mediated cleavage induced by the EGS is specific for the target
CCR5
but not the closely related CXCR4. Our results provide direct evidence that EGS RNAs against
CCR5
are effective and specific in blocking HIV infection and growth. These results also demonstrate the feasibility to develop highly effective EGSs for anti-HIV therapy.
...
PMID:RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1. 2350 33